Amgen looks to multispecifics for long-term growth

As Amgen maps its long-term growth strategy, the company is building the foundation of its future pipeline on the same multispecific concept it helped pioneer, but with modern tools that could help it regain a competitive edge. 

Amgen Inc. (NASDAQ:AGMN) is trading in the legacy bispecific T cell engager technology behind Blincyto blinatumomab for more innovative multispecific technologies that build on the company’s experience with the modality, and provide an opportunity to reclaim the leadership position it once held...